| Product Code: ETC9679687 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Thailand Biosimilar Monoclonal Antibody Market Overview |
3.1 Thailand Country Macro Economic Indicators |
3.2 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, 2021 & 2031F |
3.3 Thailand Biosimilar Monoclonal Antibody Market - Industry Life Cycle |
3.4 Thailand Biosimilar Monoclonal Antibody Market - Porter's Five Forces |
3.5 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Thailand Biosimilar Monoclonal Antibody Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic diseases in Thailand |
4.2.2 Growing demand for affordable healthcare solutions |
4.2.3 Favorable government initiatives to promote biosimilars adoption |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for biosimilar approval |
4.3.2 Limited awareness and understanding of biosimilars among healthcare professionals |
4.3.3 Challenges related to manufacturing complexity and quality control |
5 Thailand Biosimilar Monoclonal Antibody Market Trends |
6 Thailand Biosimilar Monoclonal Antibody Market, By Types |
6.1 Thailand Biosimilar Monoclonal Antibody Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Adalimumab, 2021- 2031F |
6.1.4 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Bevacizumab, 2021- 2031F |
6.1.5 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Infliximab, 2021- 2031F |
6.1.6 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Rituximab, 2021- 2031F |
6.1.7 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Trastuzumab, 2021- 2031F |
6.1.8 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Thailand Biosimilar Monoclonal Antibody Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Oncology, 2021- 2031F |
6.2.3 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Autoimmune diseases, 2021- 2031F |
6.2.4 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Thailand Biosimilar Monoclonal Antibody Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Cancer treatment centers, 2021- 2031F |
6.3.4 Thailand Biosimilar Monoclonal Antibody Market Revenues & Volume, By Others, 2021- 2031F |
7 Thailand Biosimilar Monoclonal Antibody Market Import-Export Trade Statistics |
7.1 Thailand Biosimilar Monoclonal Antibody Market Export to Major Countries |
7.2 Thailand Biosimilar Monoclonal Antibody Market Imports from Major Countries |
8 Thailand Biosimilar Monoclonal Antibody Market Key Performance Indicators |
8.1 Adoption rate of biosimilar monoclonal antibodies in Thailand |
8.2 Number of clinical trials and research studies conducted on biosimilar monoclonal antibodies |
8.3 Rate of healthcare professionals trained in prescribing and administering biosimilar monoclonal antibodies |
9 Thailand Biosimilar Monoclonal Antibody Market - Opportunity Assessment |
9.1 Thailand Biosimilar Monoclonal Antibody Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Thailand Biosimilar Monoclonal Antibody Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 Thailand Biosimilar Monoclonal Antibody Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Thailand Biosimilar Monoclonal Antibody Market - Competitive Landscape |
10.1 Thailand Biosimilar Monoclonal Antibody Market Revenue Share, By Companies, 2024 |
10.2 Thailand Biosimilar Monoclonal Antibody Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here